Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| 1 |
AbbVie
ABBV
|
+$4.73B |
| 2 |
Chevron
CVX
|
+$1.09B |
| 3 |
Qualcomm
QCOM
|
+$775M |
| 4 |
American International
AIG
|
+$707M |
| 5 |
Freeport-McMoran
FCX
|
+$553M |
Top Sells
| 1 |
MON
Monsanto Co
MON
|
+$1.72B |
| 2 |
STJ
St Jude Medical
STJ
|
+$1.56B |
| 3 |
Baidu
BIDU
|
+$1.24B |
| 4 |
Amgen
AMGN
|
+$974M |
| 5 |
Verizon
VZ
|
+$680M |
Sector Composition
| 1 | Healthcare | 19.37% |
| 2 | Technology | 11.55% |
| 3 | Communication Services | 10.85% |
| 4 | Consumer Staples | 10.39% |
| 5 | Industrials | 10.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Truist Financial
TFC
$58.3B
| $236M | 0.08% |
6,615,000
-1,046,000
| -14% | -$37.2M |
|
202
Ultragenyx Pharmaceutical
RARE
$2.92B
| $234M | 0.08% |
4,778,169
+11,696
| +0.2% | +$572K |
|
203
TE Connectivity
TEL
$62B
| $232M | 0.08% |
4,068,461
-2,939,888
| -42% | -$168M |
|
204
CME Group
CME
$94.5B
| $231M | 0.08% |
2,370,428
-356,572
| -13% | -$34.7M |
|
205
Capital One
COF
$143B
| $229M | 0.08% |
3,610,101
+410,101
| +13% | +$26M |
|
206
Myriad Genetics
MYGN
$674M
| $229M | 0.08% |
7,482,135
-1,138,704
| -13% | -$34.8M |
|
207
Ralph Lauren
RL
$19.1B
| $229M | 0.08% |
2,550,003
+400,003
| +19% | +$35.8M |
|
|
FNSR
208
DELISTED
Finisar Corp
FNSR
| $224M | 0.08% |
12,815,280
+1,086,000
| +9% | +$19M |
|
209
Omnicom Group
OMC
$15B
| $221M | 0.08% |
2,706,334
+106,334
| +4% | +$8.67M |
|
210
D.R. Horton
DHI
$53B
| $210M | 0.07% |
6,685,000
| – | – |
|
211
Generac Holdings
GNRC
$10.8B
| $205M | 0.07% |
5,877,869
-279,557
| -5% | -$9.77M |
|
212
Markel Group
MKL
$24.7B
| $203M | 0.07% |
212,852
| – | – |
|
|
AVP
213
DELISTED
Avon Products, Inc.
AVP
| $202M | 0.07% |
53,360,808
+105,467
| +0.2% | +$399K |
|
214
Weatherford International
WFRD
$4.48B
| $199M | 0.07% |
+35,827,617
| New | +$199M |
|
215
Essent Group
ESNT
$6.29B
| $198M | 0.07% |
9,072,989
+1,180,000
| +15% | +$25.7M |
|
|
TMH
216
DELISTED
Team Health Holdings Inc
TMH
| $197M | 0.07% |
4,854,274
+4
| +0% | +$163 |
|
|
FDC
217
DELISTED
First Data Corporation
FDC
| $196M | 0.07% |
17,736,768
+11,613,227
| +190% | +$129M |
|
218
Oshkosh
OSK
$8.77B
| $196M | 0.07% |
4,107,223
-2,128,377
| -34% | -$102M |
|
|
BLUE
219
DELISTED
bluebird bio
BLUE
| $196M | 0.07% |
349,225
+302
| +0.1% | +$169K |
|
220
SM Energy
SM
$3.07B
| $195M | 0.07% |
7,208,940
+304,076
| +4% | +$8.21M |
|
|
STJ
221
DELISTED
St Jude Medical
STJ
| $187M | 0.06% |
2,396,930
-19,989,217
| -89% | -$1.56B |
|
222
Novartis
NVS
$240B
| $186M | 0.06% |
2,520,486
| – | – |
|
223
TJX Companies
TJX
$155B
| $186M | 0.06% |
4,815,484
+15,484
| +0.3% | +$598K |
|
|
CRZO
224
DELISTED
Carrizo Oil & Gas Inc
CRZO
| $186M | 0.06% |
5,176,973
+1,242,353
| +32% | +$44.5M |
|
225
JB Hunt Transport Services
JBHT
$13.4B
| $185M | 0.06% |
2,283,703
+228,184
| +11% | +$18.5M |
|